Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0.00342465753424665 -0.0136986301369862 -0.0136986301369862
Stock impact report

Immunomedics Competitor Threatens To Leapfrog Approval With Breakthrough Therapy Designation [Seeking Alpha]

Galectin Therapeutics, Inc (GALT)  More Company Research Source: Seeking Alpha
Last galectin therapeutics, inc earnings: 11/12 08:00 am Check Earnings Report
PDF Immunomedics IMMU December 3rd 2019 June 2, 2020 OTCQB:CYDY Semantic Scholar Old Tech versus New Tech Cancer death rates have been falling 1.5% a year since 1991, but in 2017, the rate increased to 2.2% 90% Antibody Drug Conjugates (ADCs) IMMU's platform technology consists of an Antibody Drug Conjugate (ADC) that is linked to a targeted drug. Sacituzumab govitecanis an antibody designed to attach to the Trop-2 receptor found on most cancer cells. Attached to it is SN-38, which is essentially a highly concentrated derivative of a chemotherapeutic agent called Irinotecan Immunomedics Corporate Presentation However, targeting a chemotherapeutic is not a new idea. In the early 2000s, Galectin Therapeutics (NASDAQ: GALT block the Galectin-3 Due to the highly targeted nature of these therapies that deliver chemo, the intention is to keep most of the toxic drugs in the tumor and reduce the side effects to the patient. However, the side effects are still concerning with most therapies. Alth [Read more]
Impact snapshot Event time: GALT
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
GALT alerts
from News Quantified
Opt-in for
GALT alerts

from News Quantified
Opt-in for
GALT alerts

from News Quantified